tbuckley/cabot-search huggingface dataset:
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status
Authors: Gail J. Roboz, Farhad Ravandi, Andrew H. Wei, Hervé Dombret, Felicitas Thol, Maria Teresa Voso, Andre C. Schuh, Kimmo Porkka, Ignazia La Torre, Barry Skikne, Jianhua Zhong, C. L. Beach, Alberto Risueño, Daniel L. Menezes, Gert Ossenkoppele, Hartmut Döhner
Journal: Blood (2022)

Measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy is predictive of early relapse and poor survival. Postremission maintenance therapy that prolongs MRD negativity or converts MRD+ patients to MRD- status may delay or prevent relapse and improve overall survival (OS). In the phase 3 QUAZAR AML-001 trial, oral azacitidine (oral-AZA; formerly CC-486), a hypomethylating agent, significantly prolonged OS and relapse-free survival (RFS) compared with placebo in patients aged ≥55 years with AML in first remission after intensive chemotherapy who were not candidates for hematopoietic stem cell transplantation. In this trial, MRD (≥0.1% leukemic cells in bone marrow) was assessed by multiparameter flow cytometry in serial samples collected at baseline and on day 1 of every 3 cycles. As expected, baseline MRD status was significantly associated with both OS and RFS. Multivariate analyses showed oral-AZA significantly improved OS and RFS vs placebo independent of baseline MRD status. Oral-AZA treatment also extended the duration of MRD negativity by 6 months vs placebo and resulted in a higher rate of conversion from MRD+ at baseline to MRD- during treatment: 37% vs 19%, respectively. In the oral-AZA arm, 24% of MRD responders achieved MRD negativity >6 months after treatment initiation. Although presence or absence of MRD was a strong prognostic indicator of OS and RFS, there were added survival benefits with oral-AZA maintenance therapy compared with placebo, independent of patients' MRD status at baseline. Registered at clinicaltrials.gov as #NCT01757535.
Safety and feasbility of abciximab treatment in rescue angioplasty Giuseppe Musumeci, Anna Sonia Petronio, Roberto Baglini, Ugo Limbruno, Giovanna Mengozzi, Giovanni Paterni, Paolo Caravelli, Mario Mariani. Cardio Thoracic Dpt University of Pisa, Pisa, Italy
Journal: Journal of the American College of Cardiology (2001)
Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies
Authors: Antonio Passaro, Julie Brahmer, Scott Antonia, Tony Mok, Solange Peters
Journal: Journal of Clinical Oncology (2022)

A proportion of patients with lung cancer experience long-term clinical benefit with immune checkpoint inhibitors (ICIs). However, most patients develop disease progression during treatment or after treatment discontinuation. Definitions of immune resistance are heterogeneous according to different clinical and biologic features. Primary resistance and acquired resistance, related to tumor-intrinsic and tumor-extrinsic mechanisms, are identified according to previous response patterns and timing of occurrence. The clinical resistance patterns determine differential clinical approaches. To date, several combination therapies are under development to delay or prevent the occurrence of resistance to ICIs, including the blockade of immune coinhibitory signals, the activation of those with costimulatory functions, the modulation of the tumor microenvironment, and the targeting T-cell priming. Tailoring the specific treatments with distinctive biologic resistance mechanisms would be ideal to improve the design and results of clinical trial. In this review, we reviewed the available evidence on immune resistance mechanisms, clinical definitions, and management of resistance to ICIs in lung cancer. We also reviewed data on novel strategies under investigation in this setting.
Transactions of the American Gynæcological Society. Vol. 7.
Authors: None E. W. A.
Journal: JAMA (1884)

Volume 7 of the society's Transactions contains a valuable list of essays and discussions by specialists in the diseases of women, in addition to which is furnished a complete Index to the gynæcological literature of all countries for the year 1881, prepared with the coöperation of Dr. J. S. Billings, U. S. A., in charge of the National Medical Library in Washington. A list of the contributors to this volume will furnish the best criterion to its value. These are: Thomas Addis Emmett, M.D.; Joseph Tabor Johnson, M.D.; Thomas M. Drysdale, A.M., M.D.; R. Stansbury Sutton, M.D.; Fordyce Barker, M.D., LL.D.; Theophilus Parvin, M.D.; J. Knowsley Thornton, M.B.C.N.; Henry J. Garrigues, A.M., M.D.; T. Gaillard Thomas, M.D.; Samuel C. Bussey, M.D.; Ely Van De Warker, M.D.; J. Collins Warren, M.D.; William L. Richardson, M.D.; Matthew D. Mann, M.D.; W. H. Baker, M.D. Dr. Thomas' name appears a second time as
PUERPERAL CONVULSIONS
Authors: F. F. Giraud
Journal: BMJ (1854)

o-.*"Me then on the other, with the thighs bent eward the abdome, ad in great distrs, moaning and zsvmg oat, d begling that something might be done to 2lieve him of his pain.He had constant vomiting of small quantities of fluid tinged with yellow bile, and could not t.,e a tauspoonful of fluid without its inducing urgent VOvntn.There was much general collapse; the pulse was ryay q&c and very small; the eyes were sunken; he had great facial anxiety; the hands and fingers were cold, clammy, and of a reddish colour; there was no elasticity of the skin or subjacent structures.The abdomen was flat, or Tather concave, below a transverse line intersecting the umn- bilicus, but a little prominent above that line.There was considerable tenderness on pressure near and above the um- bilicus.Dr. Ridge detailed to me with great precision and exact- ness the history and succession of the patient's symptoms, suggesting, with Mr. Chapman, the propriety of performingr gastrotomy immnediately.This recommendation being in perfect accordance with my own experience of previously observed cases, I proceeded to make an incision in the median line about three inches long, beginning a little above and to the left of the umibilicus, and extendina it ,downwards.The linea alba was exposed; this was divided vertically, first close to the umbilicus, until the peritoneum was brought into view.A portion of this membrane was pinched up by the finger and thumb, and opened with a
Abstract 17274: Timed up and Go Test Predicts One-Year Mortality Among Patients Cardiovascular Events After Percutaneous Coronary Intervention
Authors: Nadeem Khan, Mandeep Singh
Journal: Circulation (2018)

Timed Up and Go test predicts one-year mortality among patients cardiovascular events after percutaneous coronary intervention Nadeem A. Khan, R. Jay Widmer, Amrit Kanwar, Mohammed A. Al-Hijji, Abdallah El Sabbagh, Ryan J. Lennon, Rajiv Gulati, Amir Lerman, Arashk Motiei, Mandeep Singh Background: Frailty is frequently seen in older adults and among patients with cardiovascular disease (CVD). Timed Up and Go Test (TUG) is a reliable and validated measure of frailty. We aim to assess 1-year mortality and stratify patients based on the performance on the test. Methods: Patients ≥55 years and referred to the cardiac catheterization laboratory underwent the TUG, a simple test to measure static and dynamic balance. We timed the patients while they were instructed to rise from the chair, walk 3 meters (or 10 feet), turn around, and walk back to the chair and sit down. Timing was divided in four categories [&lt;7 sec (controls), 8-10 sec, 11-14 sec, and &gt; 15 sec]. Mortality at one year was evaluated using a Cox proportional hazards model. Results: Those with TUG &gt;15s were older (75.8 ±9.1years vs. 71.2±9.2 years in controls; P&lt;0.001) and more women (42% vs. 29%) had TUG &gt;15s, P=0.002. Patients with TUG &gt;15 s had a significantly increased risk of mortality on follow-up (HR 3.88, 95% CI 1.97-7.66; P&lt;0.001, Figure) which remained significant after adjusting for age and sex (HR 1.86, 95% CI 1.05, 3.30). Conclusions: The TUG test predicts one year mortality among patients referred to the cardiac catheterization laboratory. These data underscore the importance of frailty assessment in patients with CVD.
Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease
Authors: Nour Kibbi, Joshua L. Owen, Brandon Worley, Jake X. Wang, Vishnu Harikumar, Malia B. Downing, Sumaira Z. Aasi, Phyu P. Aung, Christopher A. Barker, Diana Bolotin, Jeremy S. Bordeaux, Todd V. Cartee, Sunandana Chandra, Nancy L. Cho, Jennifer N. Choi, Kee Yang Chung, William A. Cliby, Oliver Dorigo, Daniel B. Eisen, Yasuhiro Fujisawa, Nicholas Golda, Thorvardur R. Halfdanarson, Christos Iavazzo, Shang I. Brian Jiang, Jean Kanitakis, Ashraf Khan, John Y. S. Kim, Timothy M. Kuzel, Naomi Lawrence, Mario M. Leitao, Allan B. MacLean, Ian A. Maher, Bharat B. Mittal, Kishwer S. Nehal, David M. Ozog, Curtis A. Pettaway, Jeffrey S. Ross, Anthony M. Rossi, Sabah Servaes, Michael J. Solomon, Valencia D. Thomas, Maria Tolia, Bryan B. Voelzke, Abigail Waldman, Michael K. Wong, Youwen Zhou, Nobuo Arai, Alexandria Brackett, Sarah A. Ibrahim, Bianca Y. Kang, Emily Poon, Murad Alam
Journal: JAMA Oncology (2022)

Extramammary Paget disease (EMPD) is a frequently recurring malignant neoplasm with metastatic potential that presents in older adults on the genital, perianal, and axillary skin. Extramammary Paget disease can precede or occur along with internal malignant neoplasms.
Evaluation of the effect of oversizing on vascular injury, thrombogenicity and neointimal hyperplasia using the magic wallstent in a porcine coronary model Qiang Bei Ping, Huang Yanming, Monika Szilard, Liu Xiaoshun, Eric Verbeken, Frans Van de Werf, Ivan De Scheerder. University Hospitals, Leuvne, Belgium
Journal: Journal of the American College of Cardiology (2001)
Correspondence on ‘NCF1-339 polymorphism is associated with altered formation of neutrophil extracellular traps, high serum interferon activity and antiphospholipid syndrome in systemic lupus erythematosus’ by Linge<i>et al</i>
Authors: George N Goulielmos, Maria I Zervou, Elias Eliopoulos
Journal: Annals of the Rheumatic Diseases (2022)
Numerical cognition: Unitary or diversified system(s)?
Authors: Avishai Henik, Moti Salti, Aviv Avitan, Elad Oz-Cohen, Yoel Shilat, H Moriah Sokolowski
Journal: Behavioral and Brain Sciences (2021)

Abstract Many researchers, including Clarke and Beck, describe the human numerical system as unitary. We offer an alternative view – the coexistence of several systems; namely, multiple systems (general magnitude, parallel individuation, and symbolic) existing in parallel, ready to be activated depending on the task/need. Based on this alternative view, we present an account for the representation of rational numbers.
Decreasing the Dose and Volume of Elective Nodal Radiotherapy in HPV-Associated Oropharyngeal Cancer
Authors: Philip E. Schaner, Ravi A. Chandra
Journal: JAMA Oncology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
TCT-589 The influence of the diabetic status on the clinical outcomes after percutaneous coronary intervention in the era of drug eluting stent: 5-year follow-up data from the Asan multi-vessel registry
Authors: Min Soo Cho, Yu Na Kim, Cheol Hyun Lee, Mineok Chang, Pil Hyung Lee, Jae-Hyung Roh, Sung-Han Yoon, Jung-Min Ahn, Duk-Woo Park, Soo-Jin Kang, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2015)
The therapeutic strategy for choosing lenvatinib in systemic therapy for unresectable hepatocellular carcinoma.
Authors: Kaoru Tsuchiya, Masayuki Kurosaki, Yutaka Yasui, Shun Kaneko, Sakura Kirino, Kento Inada, Yuki Tanaka, Shun Ishido, Koji Yamashita, Tsubasa Nobusawa, Yuka Hayakawa, Hiroaki Matsumoto, Tatsuya Kakegawa, Mayu Higuchi, Kenta Takaura, Shohei Tanaka, Chiaki Maeyashiki, Nobuharu Tamaki, Hiroyuki Nakanishi, Namiki Izumi
Journal: Journal of Clinical Oncology (2022)

447 Background: In systemic therapy for unresectable HCC, atezolizumab plus bevacizumab is recommended as first-line, and there are no established strategies after the immunotherapy. Lenvatinib (LEN) showed a high radiological response rate both in clinical trials and real-world practice, while it was reported that age and ALBI grade 2 were associated with the discontinuation of LEN. The aim of this study is to investigate the best candidates for LEN therapy by using clinical variables. Methods: A total of 104 patients who received LEN at our institution between Apr 2018 and Feb 2021 was enrolled. The risk factors associated with overall survival (OS) and progression-free survival (PFS) were analyzed by a Cox proportional hazard model. Results: The median observation period was 12.8 months, and the median duration of LEN was 4.5 months. The median age was 74 years, and 90 patients were Child-Pugh A. BCLC stage B patients were 43%, and median AFP was 172 ng/mL. The median OS and PFS were 17.9 and 6.2 months. In this study, 72 patients received LEN as the first line. In a multivariate analysis of first-line patients, ECOG PS≥1, modified ALBI 2b or 3, AFP≥400 ng/mL, the existence of major vascular invasion (MVI), and neutrophil to lymphocyte ratio (NLR)≥2.8 were significant risk factors associated with OS and PFS. The median OS in patients with 0-1 risk factor (n = 33) was significantly longer than the patients with 2-5 risk factors (n = 39) (22.3 vs. 16.7 months, p &lt;.0001). The median PFS in patients with no risk factor (n = 10) was 13.8 months, while the median PFS was 4.8 months in the patients with ≥2 risk factors. Among 28 patients without MVI and treated with LEN as second or later line, the median OS of the patients with 0-2 risk factors was significantly longer than those with 3-4 risk factors (21.7 vs. 7.7 months p = 0.0008). The median PFS in patients with 0-1 risk factor was 14.7 months, even though they had an experience of systemic therapy. Conclusions: LEN is strongly recommended to the patients with ECOG PS0, modified ALBI 1 or 2a, AFP &lt; 400ng/mL, no MVI, and low NLR (&lt; 2.8). When the patients would fulfill all these conditions, the median OS and PFS is over 20 and 12 months, both in patients with and without experience of systemic therapy.
Allergy abstracts
Authors: David Stein Sufleern, Harold Friedman, Ohio Monroe, Coleman Stamford, Walzer Bridgeport, N Berger Freehold, Tvln- Kahn, Te Announcement, Andre Codispoti Su&w, N Juana, C Glendora, Calif Goldman, Yorktown Heights, N Mural1
Journal: Journal of Allergy and Clinical Immunology (1983)
Simultaneous endocardial and epicardial microelectrode catheter mapping in patients with non ischemic cardiomyopathy and refractory sustained ventricular tachycardia Angelo A. V. de Paola, Ge�rgia G. Silva, Luiz R. Leite, Roberto L. Farias, Almino Rocha Neto. Federal University of S�o Paulo - Paulista School of Medicine, S�o Paulo, Brazil
Journal: Journal of the American College of Cardiology (2001)
BFGF increases atherosclerotic plaque in the aorta of hyperlipidemic rabbits Dmitri V. Baklanov, Danesh S. Rao, Anne M. Pippen, Creig F. Donatucci, Brian H. Annex. Hospital of Saint Raphael and Yale University School of Medicine, New Haven, CT, Duke University Medical Center, Durham, NC
Journal: Journal of the American College of Cardiology (2001)
WINCKEL ON WESTERN OBSTETRICIANS.
Journal: JAMA (1890)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Initial observation of contrast profiles for 3D and 2D MRI sequences in MR-guided radiation therapy for locally advanced pancreatic cancer.
Authors: Gobind S. Gill, Brady Hunt, Rongxiao Zhang, Benjamin B. Williams, Charles R. Thomas, Bassem I. Zaki
Journal: Journal of Clinical Oncology (2022)

541 Background: MR-guided stereotactic body radiation therapy (MR-SBRT) is a novel method of treating mobile tumors with soft-tissue gating and on-table adaptive planning. In our experience using the ViewRay MRIdian system (VR) for treating locally advanced pancreatic cancer (PA) with MR-SBRT, the true-fast imaging with steady-state free precession (TRUFI) sequences on the VR impart differing intensities for relevant structures seen on the pre-treatment high resolution 3D MRI (3D MRI) versus the real-time 2D cine MRI (2D cine) used for target tracking. Since these variations can confound target tracking selection, we propose that an understanding of the differing contrast profiles could improve selection of tracking structures and optimize treatment delivery. Methods: We retrospectively reviewed both 3D MRI and 2D cine images for patients (pts) with PA (n =20) treated on the VR. At simulation, an appropriate tracking target was identified and contoured on a single 3mm sagittal slice of the 3D MRI. This sagittal slice was directly compared to the registered 7mm 2D cine to identify structures with notable discrepancies in signal intensity. The 3D MRI was then explored in additional planes to confirm structure identities. For quantitative verification of the clinically observed differences, the pixel intensity distributions of 3D MRI and 2D cine DICOM image datasets were statistically compared. Results: In all pts reviewed, arteries (aorta, celiac, SMA) appeared with similar contrast profiles on both images. However, veins (portal vein, SMV) appeared hypointense on 3D MRI but hyperintense on 2D cine. Biliary structures appeared hyperintense on 3D MRI but only mildly hyperintense on 2D cine. The pixel intensity distributions extracted from 3D MRI and 2D cine images were confirmed to differ significantly (two sample Kolmogorov-Smirnov test; test statistic =0.40; p &lt; 0.001). Conclusions: There are significant variations in image intensity between the initial treatment planning 3D MRI and the immediate pre-treatment 2D cine obtained with the VR. Understanding these discrepancies can guide radiation oncologists in choosing optimal tracking targets. Future work will focus on identifying the particular causes and frequencies of target tracking failures and exploring alternative tracking algorithms using artificial intelligence which could ultimately allow for VMAT on the ViewRay system.
Rational Design Of Antiviral Agents
Authors: M. McKinlay
Journal: The Annual Review of Pharmacology and Toxicology (1989)

Over the past two decades, deadly coronaviruses, with the most recent being the severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) 2019 pandemic, have majorly challenged public health. The path for virus invasion into humans and other ...Read More
Table of Contents
Authors: P Coates, Germaine Wong, Peter Stenvinkel, Paul Shiels, Johanna Painer, J Miranda, Barbara Natterson-Horowitz, Richard Johnson, Ziad Massy, Tilman Drueke, Carsten Wagner, Anna Williams, Mingyu Liang, Brian Nankivell, Kate Robson, A Kitching, Anna Francis, Craig Gordon, Ronald Perrone, Vinh Huynh, Marie-Pierre Audrézet, John Sayer, Albert Ong, Siriane Lefevre, Valoris Le Brun, Aurore Després, Sarah Senum, Fouad Chebib, Miguel Barroso-Gil, Chirag Patel, Andrew Mallett, Himanshu Goel, Amali Mallawaarachchi, Albertien Van Eerde, Eléonore Ponlot, Marc Kribs, Yannick Le Meur, Peter Harris, Emilie Cornec-Le Gall, Federica Fazzini, Claudia Lamina, Julia Raschenberger, Ulla Schultheiss, Fruzsina Kotsis, Sebastian Schönherr, Hansi Weissensteiner, Lukas Forer, Inga Steinbrenner, Heike Meiselbach, Barbara Bärthlein, Christoph Wanner, Kai-Uwe Eckardt, Anna Köttgen, Florian Kronenberg, Gckd Investigators, Samar Said, Nelson Leung, Mariam Alexander, Lynn Cornell, Mary Fidler, Joseph Grande, Loren Herrera, Sanjeev Sethi, Pingchuan Zhang, Samih Nasr, Candice Roufosse, Elizabeth Curtis, Linda Moran, Michael Hollinshead, Terry Cook, Brian Hanley, Catherine Horsfield, Desley Neil, Kelly Smith, Shreeram Akilesh, Charles Alpers, Roberto Nicosia, Stephan Kemmner, Markus Guba, Ulf Schönermarck, Manfred Stangl, Michael Fischereder, Gabriela Gautier-Vargas, Clement Baldacini, Ilies Benotmane, Nicolas Keller, Peggy Perrin, Bruno Moulin, Sophie Caillard, Kenar Jhaveri, Lea Meir, Bessy Suyin, Flores Chang, Rushang Parikh, Rimda Wanchoo, Maria Barilla-Labarca, Vanesa Bijol, Negin Hajizadeh, Alexandre Candellier, Éric Goffin, Juhan Lee, Kyu Huh
Journal: Kidney International (2020)
Trends in all-cause mortality among people with diagnosed diabetes in high-income settings: a multicountry analysis of aggregate data
Authors: Dianna J Magliano, Lei Chen, Bendix Carstensen, Edward W Gregg, Meda E Pavkov, Agus Salim, Linda J Andes, Ran Balicer, Marta Baviera, Juliana C N Chan, Yiling J Cheng, Helene Gardiner, Hanne L Gulseth, Romualdas Gurevicius, Kyoung Hwa Ha, György Jermendy, Dae Jung Kim, Zoltán Kiss, Maya Leventer-Roberts, Chun-Yi Lin, Andrea O Y Luk, Stefan Ma, Manel Mata-Cases, Didac Mauricio, Gregory A Nichols, Santa Pildava, Avi Porath, Stephanie H Read, Cynthia Robitaille, Maria Carla Roncaglioni, Paz Lopez-Doriga Ruiz, Kang-Ling Wang, Sarah H Wild, Naama Yekutiel, Jonathan E Shaw
Journal: The Lancet Diabetes & Endocrinology (2022)
Albuminuria is independently associated with left ventricular hypertrophy in the hypertensive population: the strong heart study Jennifer E. Liu, Vittorio Palmieri, David C. Robbins, Mary J. Roman, Jonathan N. Bella, Richard R. Fabsitz, Elisa T. Lee, Thomas K. Welty, Barbara V. Howard, Richard B. Devereux. The New York Hospital Cornell Medical Center, New York, NY
Journal: Journal of the American College of Cardiology (2001)